Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Exelixis
Neonc Technologies, Inc.
Bristol-Myers Squibb
Fujian Medical University
Aulos Bioscience, Inc.
Yale University
Mayo Clinic
Maastricht University Medical Center
Memgen, Inc.
Iovance Biotherapeutics, Inc.
Gustave Roussy, Cancer Campus, Grand Paris
Maria Sklodowska-Curie National Research Institute of Oncology
University of Pittsburgh
German Society for Pediatric Oncology and Hematology GPOH gGmbH